PharmaCyte Biotech will implement a 1-for-19 reverse stock split effective November 13, 2026, with the security moving to a new CUSIP number of 71715X302.
PharmaCyte Biotech will effect a one-for-nineteen (1-19) reverse split of its Common Stock effective Friday, November 13, 2026, with the CUSIP changing to 71715X302. This is a mechanical corporate action that leaves the company's value unchanged; the split is neutral for price fundamentals, though reverse splits on micro-cap biotechs can carry a mildly negative signaling effect. Market makers may need to re-register.
PharmaCyte Biotech, Inc. (PMCB) announced a one-for-nineteen (1-19) reverse stock split of its common stock. The corporate action is scheduled to become effective on Friday, November 13, 2026, and will be accompanied by a change in the company's CUSIP number to 71715X302.
On November 13, 2026 every 19 shares of PharmaCyte Biotech Common Stock will be consolidated into one share, and the security will trade under a new CUSIP number (71715X302). The total value of a shareholder's position is unchanged by the split itself.
A reverse split mechanically multiplies the share price by 19 but does not change the company's underlying value. This Nasdaq alert contains no business or pipeline news, so it provides no fundamental reason for the price to rise or fall.